Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NovaDel neurology news

NovaDel said it will submit a recommendation to shareholders to dissolve the company and liquidate its assets. Pending shareholder approval and the sale of NovaDel's last remaining drug

Read the full 283 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE